Profound Medical Corp. (PROF) - Q2 2026 10-Q Summary
Business Context and Reporting Period
Profound Medical Corp. is a commercial-stage medical device company developing AI-powered, MRI-guided, incision-free therapies for tissue ablation. Its lead product, TULSA-PRO, treats prostate conditions, while Sonalleve treats uterine fibroids and bone metastases. This voluntary Form 10-Q covers the quarterly period ended June 30, 2026. The company is a Foreign Private Issuer and a smaller reporting company.
Key Financial Metrics (Six Months Ended June 30, 2026)
| Metric | Value (USD in thousands) |
|---|---|
| Revenue | $7,820 |
| Gross Profit | $5,779 |
| Gross Margin | 74% |
| Operating Loss | $(19,087) |
| Net Loss | $(16,593) |
| Net Loss Per Share (Basic/Diluted) | $0.46 |
| Cash and Cash Equivalents | $38,271 |
| Long-Term Debt | $4,507 |
| Operating Cash Flow | $(19,921) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 62% year-over-year (YoY) to $7.82 million, driven by higher capital equipment sales in the U.S. and overseas. Capital equipment revenue rose 154% to $3.73 million, while recurring revenue grew 22% to $4.09 million.
- Expense Reduction: Total operating expenses decreased 13% YoY to $24.87 million. Selling, General, and Administrative (SG&A) expenses dropped 20% due to reduced headcount, travel, and insurance costs. R&D expenses remained flat.
- Net Loss Improvement: Net loss decreased 37% YoY to $16.59 million. This improvement was significantly aided by a $1.86 million foreign exchange gain (compared to a $2.13 million loss in the prior year) and lower operating expenses.
- Liquidity: Cash balances decreased from $59.72 million at year-end 2025 to $38.27 million, reflecting a net cash outflow from operations of $19.92 million.
Outlook, Risks, and Management Commentary
- Liquidity Runway: Management expects existing cash and product sales to fund operations for at least the next 12 months. Expenses are expected to increase due to continued commercialization of TULSA-PRO and Sonalleve.
- Debt Covenants: The company is in compliance with its CIBC Credit Agreement covenants as of June 30, 2026. Covenants require unrestricted cash to exceed the greater of the six-month loss or $10 million, and revenue to be 15% higher than the prior year's same period.
- Capital Allocation: Proceeds from a December 2025 offering ($40.8 million net) are being utilized for TULSA-PRO commercialization ($17.1 million spent to date), Sonalleve development ($4.3 million), and working capital ($5.6 million).
- Risks: Future compliance with debt covenants depends on achieving specific revenue and EBITDA targets. The company may require additional capital for R&D or expansion, which could result in dilution or restrictive covenants.
Investor Verification Checklist
- Covenant Compliance: Verify continued adherence to CIBC financial covenants, specifically the revenue growth requirement (15% YoY) and unrestricted cash minimums.
- Cash Burn Rate: Monitor the sustainability of the $19.9 million operating cash burn over the next 12 months against the $38.3 million cash balance.
- Revenue Mix: Assess the sustainability of the surge in capital equipment sales ($3.73M vs $1.47M prior year) versus recurring revenue growth.
- Foreign Exchange Impact: Note that the significant reduction in net loss was partially driven by a favorable foreign exchange swing; evaluate core operational performance excluding FX volatility.
- Debt Maturity: Confirm the status of the revolving line of credit maturing on March 3, 2027, and the conditions for increasing the commitment.